TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19439878
Drug: IL bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL bleomycin (0.1% solution with concurrent anesthesia)
Study: 18042591
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) for induction therapy with corticosteroids for 24 weeks
Study: 18042591
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) for maintenance therapy with corticosteroids
Study: 18042591
Drug: Cyclophosphamide for
Normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide for induction therapy with corticosteroids for 24 weeks
Study: 18042591
Drug: Azathioprine for
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine for maintenance therapy with corticosteroids
Study: 15088305
Drug: Cetylated fatty
Normalized name: Cetyl Alcohol
DrugBank: Cetyl alcohol (DB09494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetylated fatty acid (CFA) topical cream
Study: 7943076
Drug: Intravaginal prostaglandin
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal prostaglandin E2 (2.5 mg)
Study: 7943076
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 (0.5 mg)
Study: 1387073
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with insulin and sulfonylurea
Study: 20684786
Drug: Structured practice
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured practice nurse reviews with a specially prepared education booklet and comprehensive baseline assessment, followed by regular 3 monthly reviews over 2 years.
Study: 10893895
Drug: Megadose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megadose heparin bolus (300 IU/kg body weight)
Study: 8671129
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy for Helicobacter pylori
Study: 8355105
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg methylprednisolone orally the evening before surgery, combined with 20 mg methylprednisolone intravenously immediately preoperatively
Study: 8355105
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg methylprednisolone orally and 20 mg intravenously
Study: 3125098
Drug: Control (GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (GH therapy)
Study: 24096862
Drug: Sequential fitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential fitting of bilateral hearing aids
Study: 23257685
Drug: mepolizumab (anti-IL-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab (anti-IL-5 monoclonal antibody)
Study: 18561877
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg bid
Study: 1334445
Drug: 2% nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nedocromil sodium eye drops (twice daily)
Study: 1334445
Drug: 2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sodium cromoglycate eye drops (four times daily)
Study: 3881088
Drug: Glucocorticosteroid formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroid formulations
Study: 25857847
Drug: i.v. parecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. parecoxib sodium 40 mg
Study: 25857847
Drug: i.v. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. placebo (saline) 2 mL
Study: 20592006
Drug: ATM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATM therapy (N=47)
Study: 7562765
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy + routine drug therapy
Study: 7438972
Drug: Oral fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenoterol 2.5 mg
Study: 7438972
Drug: Oral fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenoterol 5 mg
Study: 7438972
Drug: Oral fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenoterol 7.5 mg
Study: 31772506
Drug: High day
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High day 1 dsDNA levels (>median; 366 ng/ml)
Study: 27852999
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin vaccine
Study: 26087078
Drug: Disease agency
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease agency language assigned to humans (e.g., 'I developed cancer')
Study: 26087078
Drug: Death-approach language
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Death-approach language (e.g., 'as death closes in on patients')
Study: 26087078
Drug: Human-approach language
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human-approach language (e.g., 'as patients close in on death')
Study: 23327232
Drug: Saliva contamination
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saliva contamination after light polymerization of the bonding agent (group 5)
Study: 21358561
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonazepam (1 mg once daily) and Deanxit for 3 weeks
Study: 21358561
Drug: Clonazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (1 mg once daily) and placebo for 3 weeks
Study: 17971582
Drug: Two-Dimensional Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-Dimensional Radiation Therapy (2DRT)
Study: 15115903
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) 0.5 mg after oral placebo (OP)
Study: 15115903
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) 0.5 mg after 80 mg isosorbide dinitrate (ISDN)
Study: 15115903
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) 0.5 mg after 120 mg isosorbide dinitrate (ISDN)
Study: 15115903
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) after long-term OP therapy
Study: 15115903
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) after long-term 80 mg ISDN therapy
Study: 15115903
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG) after long-term 120 mg ISDN therapy
Study: 7272174
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 120 mg
Study: 15115903
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 80 mg once-daily
Study: 15115903
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 120 mg once-daily
Study: 11763107
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg t.i.d.)
Study: 9893926
Drug: Timonil retard
Normalized name: Timonil Retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timonil retard (test formulation)
Study: 8061389
Drug: Chemotherapy (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-fluorouracil, its analogues, and mitomycin C)
Study: 947849
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (700 IU)
Study: 947849
Drug: Subunit vaccine
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccine (2100 IU)
Study: 947849
Drug: Split vaccine
Normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split vaccine (800 IU)
Study: 29064884
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral antibiotics and intravenous antimicrobial prophylaxis
Study: 29546345
Drug: Multivitamin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin use during treatment
Study: 29546345
Drug: Other supplement
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other supplement use (before diagnosis or during treatment)
Study: 25023433
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous hyoscine-N-butyl bromide (HBB)
Study: 16643550
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL saline)
Study: 9586474
Drug: Mk II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mk II self‐tapping implants
Study: 9586474
Drug: Standard implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implants
Study: 31385800
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight iron dextran (1 g)
Study: 29332050
Drug: Supplemental L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental L (10 mg), MZ (10 mg), and Z (2 mg) daily for 12 months
Study: 26610430
Drug: Testosterone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (1000 mg T undecanoate)
Study: 25445074
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for late-life GAD, 10 sessions
Study: 22245877
Drug: Antimuscarinic agent
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic agent (solifenacin)
Study: 22245877
Drug: No antimuscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimuscarinic agent
Study: 1712835
Drug: Etidronate disodium
Normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate disodium (EHDP) 5 mg/kg/d
Study: 7040950
Drug: Oral glucose‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose‐electrolyte solution containing 90 mmol of sodium per liter
Study: 7040950
Drug: Oral glucose‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose‐electrolyte solution containing 50 mmol of sodium per liter
Study: 10911006
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous therapy
Study: 22348071
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with EMLA cream
Study: 2187176
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg/kg)
Study: 94008
Drug: Photocoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocoagulation treatment in one eye
Study: 16527229
Drug: Control eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eyes (no treatment)
Study: 31144720
Drug: Antibiotic catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic catheter lead coverage (group A)
Study: 31144720
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic protection (group B)
Study: 28724365
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab (500 mg on days 1 and 15)
Study: 28724365
Drug: Leflunomide (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (10-20 mg/day)
Study: 23082538
Drug: Buprenorphine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.2 mg/kg s.c.)
Study: 23082538
Drug: Hydromorphone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.5 mg/kg s.c.)
Study: 23082538
Drug: Buprenorphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.1 mg/kg)
Study: 23082538
Drug: Buprenorphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (1 mg/kg)
Study: 3324596
Drug: Linear incision
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear incision plus curettage under antibiotic cover
Study: 20338067
Drug: Purell Instant
Normalized name: Ethanol 65% Topical application Spray [PURELL INSTANT HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purell Instant Hand Sanitizer (1.6 g)
Study: 20338067
Drug: Alcare plus
Normalized name: Alcare Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcare plus (1.6 g)
Study: 20338067
Drug: Water (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (1.6 g)
Study: 19590518
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intracameral triamcinolone acetonide (TA)
Study: 18162061
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate 1% eyedrops (6 times per day for 7 days, then 4 times per day for 15 days)
Study: 12736475
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I antiarrhythmic drug infusion for 10 min
Study: 9583853
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for severe malnutrition
Study: 2119323
Drug: Tolrestat 200
Normalized name: tolrestat 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolrestat 200 mg once daily
Study: 8126317
Drug: Methylphenidate (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.6 mg/kg)
Study: 324389
Drug: Josamycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (1.5 g/day)
Study: 324389
Drug: Erythromycin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1.0 g/day)
Study: 31808984
Drug: Intramuscular betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular betamethasone
Study: 25992536
Drug: UPCR weighted
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPCR weighted by estimated daily urine creatinine excretion (eUCr)
Study: 19702681
Drug: Rough-surface implants
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surface implants (TiUnite, n = 45)
Study: 19702681
Drug: Hybrid surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid surface implants (Restore, n = 45)
Study: 19702681
Drug: Rough-surface with
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rough-surface with microthreads implants (Hexplant, n = 45)
Study: 11509226
Drug: Ethanol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.8 g/kg, max 60 g males, 50 g females)
Study: 28663633
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 8 mg with ropivacaine 0.2% (Group B)
Study: 28663633
Drug: Caudal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine 0.2% with dexamethasone 8 mg (Group C)
Study: 26491204
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical moisturizer during the study period
Study: 23140912
Drug: FPG ≥126
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG ≥126 mg/dl and HbA1c ≥6.5%
Study: 19153828
Drug: No endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endocrine treatment (Control)
Study: 17258182
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment for one year
Study: 15530262
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin (100 mg/m(2))
Study: 15530262
Drug: Daily low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily low-dose cisplatin (4 mg/m(2))
Study: 19253522
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker monotherapy
Study: 9749163
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (75 mg/day)
Study: 8168557
Drug: Clotrimazole regimen
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole regimen (10 mg twice daily) with Mycostatin (500,000 I.U. four times daily), Benadryl, and Cepacol mouthwash
Study: 28314838
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1,000 mg with prednisone 5 mg twice daily and BEZ235 200 mg twice daily
Study: 16034044
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen treatment for 2 years
Study: 16543298
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment team (127 participants)
Study: 9122104
Drug: Empirical antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotic treatment for suspected pyogenic abscess
Study: 1362746
Drug: Amoxycillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin‐clavulanic acid (2.2 g)
Study: 18426345
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g)
Study: 3873345
Drug: Murine antihuman
Normalized name: Murine Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murine antihuman T-cell monoclonal antibody (mcAb) therapy
Study: 3873345
Drug: Subsequent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent treatment with ATG after mcAb failure
Study: 3873345
Drug: Toxicity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicity of mcAb therapy
Study: 27180107
Drug: Higher NMR
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher NMR (faster nicotine metabolism) in White smokers
Study: 27180107
Drug: Higher NMR
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher NMR (faster nicotine metabolism) in African American smokers
Study: 24595629
Drug: intensive glycemia
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive glycemia treatment
Study: 24595629
Drug: intensive BP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive BP treatment
Study: 24595629
Drug: both intensive
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both intensive glycemia and BP treatment
Study: 29863695
Drug: Antidepressant +
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant + tranquilizer + antipsychotic agent
Study: 29863695
Drug: Antidepressant +
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant + tranquilizer
Study: 29863695
Drug: Antidepressant +
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant + tranquilizer + mood stabilizer
Study: 22337244
Drug: Sulfasalazine up
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine up to 3 g daily
Study: 15632821
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (300 mg/d for 2 weeks preoperatively)
Study: 11773297
Drug: Non-anthracycline-based adjuvant
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anthracycline-based adjuvant therapies
Study: 8062524
Drug: Stable isotope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable isotope 54Fe (2.8 mg) given in aqueous form
Study: 8062524
Drug: Stable isotope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable isotope 54Fe (2.8 mg) taken with a meat meal
Study: 3302874
Drug: Clavulanic acid-amoxicillin
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clavulanic acid-amoxicillin (ACA)
Study: 23380178
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 100 µg twice daily plus placebo tablet once daily
Study: 23380178
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 100 µg and salmeterol 50 µg twice daily (combination inhaler) plus placebo tablet once daily
Study: 23380178
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 100 µg twice daily plus montelukast 5-mg tablet once daily
Study: 21979989
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 µg twice daily)
Study: 16581422
Drug: Subthreshold 810-nm-diode
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold 810-nm-diode laser treatment